BIAF bioAffinity Technologies, Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1712762 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.5%
TTM net income YoY-4.6%
TTM EPS YoY182.9%
Revenue 3-yr CAGR37.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-246.1%
Net margin-278.9%
FCF margin-235.9%
EBITDA margin-239.5%
Returns
ROE-240.5%
ROA-161.4%
ROIC (approx.)-827.2%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets48.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-270.95x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6.16M | $9.36M | $2.53M | $6.90M | — |
| Cost of revenue | — | — | — | $467 | — |
| Gross profit | — | — | — | $4,336 | — |
| R&D expense | $1.38M | $1.46M | $1.47M | $1.38M | $1.01M |
| SG&A expense | $9.91M | $9.94M | $6.79M | $2.48M | $1.07M |
| Operating income | -$10.57M | -$8.95M | -$7.97M | -$4.01M | -$2.21M |
| Interest expense | $44,372 | $92,475 | $37,125 | $2.53M | $1.00M |
| Pretax income | -$14.87M | -$9.03M | -$7.92M | -$8.15M | -$6.32M |
| Income tax | $44,042 | $11,650 | $20,993 | $2,459 | $1,950 |
| Net income | -$14.91M | -$9.04M | -$7.94M | -$8.15M | -$6.33M |
| EBITDA | -$10.07M | -$8.35M | -$7.72M | -$4.00M | -$2.20M |
| EPS (basic) | -8.66 | -22.50 | -0.91 | -1.81 | -2.36 |
| EPS (diluted) | -8.66 | -22.50 | -0.91 | -1.81 | — |
| Weighted avg. shares (diluted) | 1.72M | 404,167 | 8.75M | 4.50M | — |
| Balance sheet | |||||
| Cash & equivalents | $6.45M | $1.11M | $2.82M | $11.41M | $1.36M |
| Receivables | — | — | — | $10,489 | — |
| Inventory | $53,548 | $27,608 | $18,484 | $5,540 | — |
| Current assets | $7.57M | $2.70M | $3.97M | $11.96M | $1.44M |
| PP&E, net | $265,593 | $375,385 | $458,633 | $214,438 | $4,633 |
| Goodwill | $1.40M | $1.40M | $1.40M | — | — |
| Intangibles | $716,806 | $775,139 | $833,472 | — | — |
| Total assets | $10.96M | $6.51M | $8.22M | $12.18M | $1.45M |
| Current liabilities | $2.91M | $3.10M | $2.25M | $1.14M | $13.04M |
| Total liabilities | $3.68M | $3.91M | $3.37M | $1.14M | $13.20M |
| Shareholders' equity | $7.28M | $2.60M | $4.86M | $11.04M | -$15.79M |
| Shares outstanding | 299,826 | 519,158 | 9.39M | 8.38M | 2.68M |
| Cash flow statement | |||||
| Operating cash flow | -$9.33M | -$7.26M | -$6.04M | -$4.07M | -$2.05M |
| Capital expenditure | $60,568 | $79,083 | $22,902 | $219,987 | — |
| Free cash flow | -$9.39M | -$7.34M | -$6.06M | -$4.29M | — |
| Investing cash flow | -$60,568 | -$79,083 | -$2.21M | -$219,987 | — |
| Financing cash flow | $14.73M | $5.63M | -$344,984 | $14.34M | $3.33M |
| Depreciation & amortization | $504,836 | $605,637 | $249,592 | $10,182 | $4,817 |
| Stock-based compensation | $671,474 | $989,681 | $748,823 | $248,592 | $43,012 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.